Skip to Content

Join the 'Opdivo' group to help and get support from people like you.

Opdivo News

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Posted 7 May 2018 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) April 16, 2018 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) as the first Immuno-Oncology combination therapy for previously untreated patients with intermediate- and poor-risk advanced renal ...

New Immunotherapy Drugs May Be Big Advance in Lung Cancer Care

Posted 16 Apr 2018 by Drugs.com

MONDAY, April 16, 2018 – Drugs designed to trigger a patient's immune system may help boost survival for those battling lung cancer, two new studies found. The first study found that when the immunotherapy drug Keytruda (pembrolizumab) was combined with standard chemotherapy, the chance that a patient would die within the next 11 months plummeted by more than 50 percent, compared with being ...

Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

Posted 14 Mar 2018 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.1 This approval will provide health care ...

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease

Posted 17 Jan 2018 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE)-- December 20, 2017 Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.1 The purpose of adjuvant therapy ...

Lung Cancer Drug, Nivolumab (Opdivo), Targets 'Hidden' HIV in French Patient

Posted 1 Dec 2017 by Drugs.com

FRIDAY, Dec. 1, 2017 – In a case that investigators say is a first, a lung cancer drug unmasked and then attacked the kind of HIV-infected cells that standard antiretroviral therapy has been unable to touch. The finding was reported on Dec. 1, which is also World AIDS Day, in the Annals of Oncology. While one AIDS expert said the findings were promising, she noted the drug did not "cure" the ...

Patients' Gut Bugs May Play Role in Cancer Care

Posted 3 Nov 2017 by Drugs.com

THURSDAY, Nov. 2, 2017 – The type of bacteria that cancer patients harbor in the gut might affect their odds of responding to certain treatments, two early studies hint. The research, in humans and mice, adds to evidence that gut bacteria play a key role in the immune system. But experts stressed it's too soon to make recommendations to cancer patients – including whether they should take ...

Bristol-Myers Squibb’s Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib

Posted 26 Sep 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) September 22, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Approval for this indication has been granted under accelerated ...

Immune-Focused Drug, Opdivo, May Be New Weapon Against Advanced Melanoma

Posted 11 Sep 2017 by Drugs.com

MONDAY, Sept. 11, 2017 – New research suggests that Opdivo – a drug that works with the immune system to fight melanoma – is more effective than the current standard of care for patients who've had surgery to remove advanced tumors. The international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma. Patients were ...

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment

Posted 2 Aug 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) August 1, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection for intravenous use for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Opdivo (Nivolumab) Offers Some Hope for a Deadly Lung Cancer

Posted 4 Apr 2017 by Drugs.com

TUESDAY, April 4, 2017 – The cancer drug Opdivo (nivolumab) may offer hope of a longer life for some patients with advanced lung cancer, a new small study finds. Currently, only about 5 percent of patients with advanced non-small-cell lung cancer survive five years or more. But that rate rose to about 16 percent among a group taking Opdivo, researchers reported Monday. "For the first time we are ...

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

Posted 10 Feb 2017 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE)-- February 2, 2017 – Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease ...

Bristol-Myers Squibb’s Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer

Posted 14 Nov 2016 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2016 --Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.1 ...

Powerful Cancer Drugs Linked to Rare Heart Risks

Posted 3 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – In rare cases, potent drugs that prompt the immune system to fight cancer may threaten the heart in the process, researchers report. Known as immunotherapy, these medications have transformed cancer treatment in recent years, sending some patients who had few options left into remission. But a report in the Nov. 3 issue of New England Journal of Medicine describes two ...

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of ...

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer, Head and Neck Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Renal Cell Carcinoma, Urothelial Carcinoma

Opdivo Patient Information at Drugs.com